Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Taber DJ et al. | Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. | 2017 | Transplantation | pmid:28658199 |
Diémé B et al. | Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. | 2014 | Transplantation | pmid:24598938 |
Kim CD et al. | Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. | 2010 | Transplantation | pmid:20842074 |
Shield CF et al. | Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. | 1997 | Transplantation | pmid:9422413 |
Demetris AJ et al. | Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. | 1992 | Transplantation | pmid:1374944 |
Demmers MW et al. | Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. | 2014 | Transplantation | pmid:24704664 |
Manitpisitkul W et al. | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. | 2009 | Transplantation | pmid:19584685 |
Dominguez J et al. | Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. | 2000 | Transplantation | pmid:11063349 |
Nogueira JM et al. | A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. | 1999 | Transplantation | pmid:10096529 |
Gregory CR et al. | Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. | 1995 | Transplantation | pmid:7533955 |
Wallia A et al. | Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. | 2010 | Transplantation | pmid:20098286 |
Vossen M et al. | Bone quality in swine composite tissue allografts: effects of combination immunotherapy. | 2005 | Transplantation | pmid:16123723 |
Qi S et al. | Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. | 2000 | Transplantation | pmid:10798741 |
McDiarmid SV et al. | Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. | 1993 | Transplantation | pmid:7685933 |
Kasahara M et al. | Role of HLA compatibility in pediatric living-related liver transplantation. | 2002 | Transplantation | pmid:12438966 |
Hudnall SD | Cardiac hypertrophy postliver transplantation: a role for FK506 and cyclosporine A? | 2002 | Transplantation | pmid:12369583 |
de Jonge H et al. | Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. | 2010 | Transplantation | pmid:20592652 |
Shibasaki S et al. | Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. | 2013 | Transplantation | pmid:23269193 |
Puig I Marà JM et al. | Reflex sympathetic dystrophy syndrome of the lower limbs in a renal transplant patient treated with tacrolimus. | 2000 | Transplantation | pmid:10919604 |
Erickson LM et al. | Microarray-based gene expression profiles of allograft rejection and immunosuppression in the rat heart transplantation model. | 2003 | Transplantation | pmid:12923448 |